Figure 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

• Changes in tumor fraction are significant predictors of clinical benefit from immune checkpoint inhibitors.
• The study highlights the importance of methylation in assessing treatment outcomes, supporting personalized therapies.
• Data was collected from the RADIOHEAD study focused on patient samples passing specific quality control metrics.
• Findings suggest that monitoring ctDNA could enhance treatment strategies for cancer patients using immune therapy.